Recently, AnkeBio obtains a new invention patent license issued by the State Intellectual Property Office with theinvention title as Preparation Method of High-Purity Recombinant Human Interferon α2b,  of which the patent lasts for 20 years.

The invention discloses a preparation method of high-purity Recombinant Human Interferon α2b, wherein the RP-HPLC purity could exceed 95% and no Met is in N end sequencing, which can effectively avoid immune reactions and side effects in patients. The acquisition of this patent is conducive to improving the company's intellectual property protection system, further giving full play to the company's independent intellectual property rights and enhancing the company's core competitiveness.